- Atlas
- Medicine & Health
- Nuclear Medicine
Nuclear Medicine
Nuclear medicine is the branch of medical imaging that makes pictures from the radiation emitted by radioactive substances placed inside the body.
7 frameworks, from 1913 to today · Medical Imaging · Medicine & Health
Overview
Nuclear medicine is the branch of medical imaging that makes pictures from the radiation emitted by radioactive substances placed inside the body1. Its practitioners do not shine a beam through a patient, as radiography does; they administer a radiopharmaceutical—a molecule tagged with a radioactive atom—and then detect the gamma rays or positrons that escape from the patient's tissues1. Because the tracer distributes itself according to the body's chemistry, the resulting image shows function rather than anatomy: where the thyroid is taking up iodine, where the heart muscle is perfused with blood, where a tumour is consuming glucose. The same principle, turned around, allows treatment: a radionuclide carried to a tumour can deliver lethal radiation to it while sparing surrounding tissue12. That dual identity—diagnosis and therapy from the same tracer principle—is what makes nuclear medicine distinct within medical imaging13.
The Tracer Principle and the First Radionuclide Tracers
The intellectual foundation of the field is the tracer principle: a radioactive atom behaves chemically like its stable counterpart, so a tiny quantity of a radioactive substance can be followed through a living system without disturbing it34. The Hungarian chemist George de Hevesy is credited with establishing this idea in the 1910s and 1920s, using radioactive lead and bismuth to trace the fate of substances in plants and animals. Hevesy's work earned him the 1943 Nobel Prize in Chemistry, and the principle he articulated became the conceptual engine of all nuclear medicine.
The first clinical application came from the thyroid. In the late 1930s, researchers at the Massachusetts Institute of Technology and Massachusetts General Hospital, including Saul Hertz and the physicist Arthur Roberts, showed that radioactive iodine—initially iodine-128, later the longer-lived iodine-131—was taken up by the thyroid gland. In 1941 Hertz treated a patient with hyperthyroidism using radioiodine, the first therapeutic use of a radionuclide in humans. The thyroid became the model organ for the field: a gland that concentrates a specific element, making it visible and treatable with a single tracer.
Organ-Specific Planar Scintigraphy
Through the 1950s and 1960s, nuclear medicine grew as a collection of organ-specific tests. The instrument was the scintillation detector—a crystal, usually sodium iodide activated with thallium, that flashes when struck by a gamma ray—coupled to a photomultiplier tube. The rectilinear scanner, developed by Benedict Cassen in the early 1950s, moved a single detector back and forth across the patient to build a two-dimensional map of radioactivity. The gamma camera, invented by Hal Anger in 1958, replaced the scanning detector with a large stationary crystal that could image the whole field at once, and it became the workhorse of planar scintigraphy for decades.
With these instruments, practitioners built a repertoire of organ-specific studies: iodine-131 scans of the thyroid; technetium-99m scans of the skeleton, liver, and spleen (technetium-99m, discovered as a generator-produced radionuclide in the 1960s, became the field's most-used tracer because of its convenient six-hour half-life and pure gamma emission); and lung perfusion scans using technetium-99m-labelled particles. Each study rested on the same logic: a radiopharmaceutical that concentrates in a particular organ makes that organ's function visible as a pattern of brightness1.
Emission Computed Tomography
Planar scintigraphy superimposed everything in the field of view onto one image, so a hot spot deep in the body could not be localized in three dimensions. The solution came from the same mathematics that produced X-ray CT: reconstruct a cross-section from many projections. In nuclear medicine this became emission computed tomography—reconstructing the distribution of a radionuclide from gamma rays detected at many angles around the patient5.
Single-photon emission computed tomography (SPECT) developed through the 1960s and 1970s, with major contributions from researchers such as David Kuhl and Ronald Jaszczak, and became clinically routine in the 1980s. SPECT detects the single gamma rays emitted by tracers like technetium-99m, using a rotating gamma camera and collimators—lead grids that restrict which rays reach the detector. Positron emission tomography (PET) took a different route: it detects the pairs of gamma rays produced when a positron annihilates with an electron, and its coincidence detection gives inherently better localization and sensitivity. PET's foundations were laid by Kuhl, Roy Edwards, and others in the 1960s and 1970s, and the first practical PET scanners appeared in the 1970s.
Metabolic and Molecular Imaging with PET
PET's great advantage was that it could image metabolism with tracers that were genuine biological molecules. The landmark tracer was fluorodeoxyglucose labelled with fluorine-18 (FDG), developed by Tatsuo Ido and colleagues at Brookhaven National Laboratory in the 1970s and brought into clinical use in the late 1970s and 1980s, notably through the work of Michael Phelps, Edward Hoffman, and colleagues at UCLA. FDG is a glucose analogue: cells that consume glucose rapidly—notably many tumours and the brain—accumulate it, and PET makes that accumulation visible. FDG-PET became a major tool in oncology, cardiology, and neurology.
The 1980s and 1990s also brought a widening repertoire of PET tracers for specific molecular targets: oxygen-15 for blood flow, carbon-11-labelled compounds for receptor studies, and later fluorine-18-labelled tracers for amyloid and other targets. The field began to call itself molecular imaging, because the tracers were reporting on molecular processes rather than gross organ function13.
Hybrid Functional-Anatomical Imaging
PET and SPECT gave exquisite functional information but poor anatomical detail1. The solution was to combine them with CT or MRI in a single device or a single imaging session, so that the functional hot spot could be laid over a sharp anatomical map1. PET/CT scanners became commercially available in the early 2000s and rapidly became standard; SPECT/CT followed. Hybrid imaging solved a practical problem—the radiologist could now say exactly where a lesion was—and it changed clinical workflows, particularly in oncology, where FDG-PET/CT became central to staging and treatment planning6.
Targeted Radionuclide Therapy
The therapeutic side of nuclear medicine has its own history, running parallel to diagnosis. Radioiodine for hyperthyroidism and thyroid cancer was the first example. In the late 20th century, the field developed targeted radionuclide therapy: attaching a therapeutic radionuclide—one emitting beta particles or alpha particles, which have short ranges in tissue—to a molecule that seeks out a tumour. Iodine-131 labelled to metaiodobenzylguanidine (MIBG) was used for neuroendocrine tumours; yttrium-90 and lutetium-177 labelled to somatostatin analogues (such as DOTATATE) targeted neuroendocrine tumours; radium-223 was developed for bone metastases in prostate cancer. The logic is the tracer principle inverted: the same targeting that makes a lesion visible can, with a different radionuclide, make it die2.
The Present
Today nuclear medicine is a mature specialty with two intertwined halves. On the diagnostic side, SPECT and PET remain the core modalities, with FDG-PET/CT and, increasingly, PSMA-PET for prostate cancer and amyloid-PET for dementia in routine use. Hybrid PET/MRI, long promised, has found a niche17. On the therapeutic side, targeted radionuclide therapy—especially lutetium-177 PSMA and DOTATATE—has expanded rapidly, and the field increasingly speaks of theranostics: using a diagnostic tracer to confirm a target, then treating with a therapeutic analogue of the same molecule. The open questions are familiar ones: how to produce and distribute short-lived radionuclides reliably, how to dosimetry—calculate the radiation dose delivered to tumour and to organs—well enough to optimize therapy, and how to bring alpha-emitting radionuclides, with their higher potency and shorter range, into wider clinical use. The tracer principle, articulated a century ago, still organizes everything the field does.
References
- Nuclear medicine (introduction, Diagnostic, Sources of radionuclides, Interventional nuclear medicine, Instrumentation, Hybrid scanning techniques), Wikipedia
- Radionuclide therapy, Wikipedia
- American Board of Nuclear Medicine, Wikipedia
- Radioactive tracer, Wikipedia
- Emission computed tomography, Wikipedia
- PET–CT, Wikipedia
- PET/MRI, Wikipedia
The frameworks of Nuclear Medicine
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1913-Present
- 1941-Present
- 1950-1985
- 1970-Present
- 1976-Present
- 2000-Present
- 2005-Present

Nuclear Medicine is a planet in Nousfarer
Its city has a tower for each of these 7 frameworks. Land, walk in, and climb one concept at a time.
Land on Nuclear MedicineRelated fields
More in Medical Imaging
- Diagnostic Radiology
- Image Reconstruction
- Imaging Informatics
- Imaging Physics
- Interventional Radiology
- Medical Image Analysis
- Medical Imaging
- Molecular Imaging
- Quantitative Imaging
See where Nuclear Medicine sits on the Map of Human Knowledge